910789-32-1

Basic information

• Product Name: methyl-[7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine
• Synonyms: methyl-[7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine
• CAS NO: 910789-32-1
• Molecular Weight: 302.357
• Mol File: 910789-32-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl-[7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine(CAS DataBase Reference)
• NIST Chemistry Reference: methyl-[7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine(910789-32-1)
• EPA Substance Registry System: methyl-[7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine(910789-32-1)

Safety Data

• Hazardous Substances Data: 910789-32-1(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 78727-16-9 4-(methylamino)-7H-pyrrolo<2,3-d>pyrimidine 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 479633-63-1 4-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 74-89-5 methylamine 

Downstream Products

• 1325182-06-6 N-methyl-7-[(4-methylphenyl)sulfonyl]-N-[(3R,4R)-4-methylpiperidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1259404-17-5 tasocitinib 
• 78727-16-9 4-(methylamino)-7H-pyrrolo<2,3-d>pyrimidine 

Relevant articles and documents

Preparation method of tofacitinib

The invention discloses a preparation method of tofacitinib. The preparation method comprises the following steps: carrying out asymmetric hydrogenation on 3-chloro-4-methylpyridine to prepare a compound III; carrying out a reaction on the compound III and a compound IV to prepare a compound V; and finally, carrying out acylation and de-protection to obtain a final product tofacitinib (I). The preparation method is simple in process route, high in total yield and purity, few in side products and suitable for industrial production.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK1α1, JNK2α2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRα, PKA, PKCα, PKD2, ROCK-II, Ros, Rsk1, SAPK2α, SAPK2β, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.